The first patient has been dosed with [212Pb]VMT01 in a phase 1/2a trial evaluating the safety of the agent in patients with ...
There were a number of notable developments for patients with kidney cancer at the symposium, Dr. Emre Yekedüz explained.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback